The study analysed that the therapeutics pipeline comprises of
approximately 19 drug candidates in different stages of development. Myastheniagravis is a chronic autoimmune disorder that acts on neuromuscular junction and
leads to the weakening of skeletal muscles. This causes loss of muscle control
in moving the body parts, such as the movement of arms and legs, breathing,
loss of eye movements, chewing, talking, and swallowing. The situation of the
disease worsens after a period of activity and improves after a period of rest.
Various companies, educational institutes and medical organizations are
collaborating for the development of drugs for the treatment of this disease.
For instance, Merck & Co., Inc. entered into a multi-targeted collaboration
and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug
discovery technology platform for the development of orally available cyclic
peptides for the treatment of myasthenia gravis.
Request Sample Pages: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis/report-sample
It has been observed that most of the drugs in the myasthenia gravis
therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under
development by Neurotune AG for the treatment of myasthenia gravis. The drug
acts as a neuromuscular junction stimulator.
Pre-Purchase Enquiry: https://www.psmarketresearch.com/send-enquiry?enquiry-url=myasthenia-gravis-therapeutics-pipeline-analysis
Some of the key players developing drugs for the treatment of myasthenia
gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and
others.
Myasthenia gravis Therapeutics Pipeline Analysis
·
By Phase
·
By Molecule Type
·
By Route of Administration
·
By Company
No comments:
Post a Comment